Name | Number of supported studies | Average coverage | |
---|---|---|---|
oligodendrocyte | 15 studies | 53% ± 16% | |
endothelial cell | 11 studies | 24% ± 6% | |
microglial cell | 8 studies | 33% ± 12% | |
dendritic cell | 7 studies | 25% ± 5% | |
macrophage | 7 studies | 30% ± 9% | |
adipocyte | 6 studies | 22% ± 5% | |
B cell | 6 studies | 19% ± 5% | |
fibroblast | 5 studies | 20% ± 6% | |
endothelial cell of lymphatic vessel | 5 studies | 23% ± 4% | |
oligodendrocyte precursor cell | 5 studies | 22% ± 6% | |
cardiac muscle cell | 4 studies | 22% ± 0% | |
ciliated cell | 4 studies | 19% ± 4% | |
myeloid cell | 4 studies | 20% ± 4% | |
monocyte | 4 studies | 27% ± 7% | |
epithelial cell | 3 studies | 34% ± 11% | |
non-classical monocyte | 3 studies | 17% ± 0% | |
alveolar macrophage | 3 studies | 31% ± 7% | |
type I pneumocyte | 3 studies | 21% ± 5% | |
basal cell | 3 studies | 29% ± 18% | |
smooth muscle cell | 3 studies | 17% ± 1% | |
plasmacytoid dendritic cell | 3 studies | 24% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 636.27 | 1445 / 1445 | 100% | 16.92 | 183 / 183 |
lung | 100% | 569.00 | 577 / 578 | 99% | 18.30 | 1149 / 1155 |
breast | 100% | 630.49 | 459 / 459 | 99% | 24.00 | 1102 / 1118 |
ovary | 100% | 427.64 | 180 / 180 | 98% | 10.53 | 422 / 430 |
stomach | 100% | 385.08 | 359 / 359 | 98% | 14.00 | 280 / 286 |
intestine | 100% | 481.88 | 966 / 966 | 98% | 12.97 | 515 / 527 |
pancreas | 100% | 394.13 | 328 / 328 | 97% | 10.12 | 173 / 178 |
uterus | 100% | 621.44 | 170 / 170 | 95% | 13.85 | 437 / 459 |
bladder | 100% | 506.76 | 21 / 21 | 95% | 11.85 | 477 / 504 |
thymus | 100% | 553.99 | 653 / 653 | 95% | 9.77 | 572 / 605 |
prostate | 100% | 509.01 | 245 / 245 | 94% | 9.52 | 473 / 502 |
skin | 100% | 597.80 | 1809 / 1809 | 93% | 12.15 | 438 / 472 |
kidney | 100% | 339.94 | 89 / 89 | 88% | 8.44 | 792 / 901 |
adrenal gland | 100% | 566.95 | 258 / 258 | 77% | 5.79 | 176 / 230 |
liver | 99% | 236.12 | 223 / 226 | 63% | 4.21 | 257 / 406 |
brain | 73% | 218.54 | 1929 / 2642 | 38% | 2.30 | 270 / 705 |
adipose | 100% | 619.55 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 616.00 | 1335 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 569.71 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 485.99 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 23.87 | 44 / 45 |
heart | 96% | 439.14 | 829 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 89% | 771.40 | 826 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 86% | 16.36 | 25 / 29 |
eye | 0% | 0 | 0 / 0 | 64% | 5.07 | 51 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0018105 | Biological process | peptidyl-serine phosphorylation |
GO_2000659 | Biological process | regulation of interleukin-1-mediated signaling pathway |
GO_0007165 | Biological process | signal transduction |
GO_0034599 | Biological process | cellular response to oxidative stress |
GO_0006468 | Biological process | protein phosphorylation |
GO_0043408 | Biological process | regulation of MAPK cascade |
GO_0046777 | Biological process | protein autophosphorylation |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0031966 | Cellular component | mitochondrial membrane |
GO_0032991 | Cellular component | protein-containing complex |
GO_0005635 | Cellular component | nuclear envelope |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0019904 | Molecular function | protein domain specific binding |
GO_0106310 | Molecular function | protein serine kinase activity |
GO_0019901 | Molecular function | protein kinase binding |
GO_0004674 | Molecular function | protein serine/threonine kinase activity |
GO_0005524 | Molecular function | ATP binding |
GO_0005515 | Molecular function | protein binding |
Gene name | VRK2 |
Protein name | non-specific serine/threonine protein kinase (EC 2.7.11.1) VRK serine/threonine kinase 2 Serine/threonine-protein kinase VRK2 (EC 2.7.11.1) (Vaccinia-related kinase 2) |
Synonyms | |
Description | FUNCTION: Serine/threonine kinase that regulates several signal transduction pathways . Isoform 1 modulates the stress response to hypoxia and cytokines, such as interleukin-1 beta (IL1B) and this is dependent on its interaction with MAPK8IP1, which assembles mitogen-activated protein kinase (MAPK) complexes . Inhibition of signal transmission mediated by the assembly of MAPK8IP1-MAPK complexes reduces JNK phosphorylation and JUN-dependent transcription . Phosphorylates 'Thr-18' of p53/TP53, histone H3, and may also phosphorylate MAPK8IP1 . Phosphorylates BANF1 and disrupts its ability to bind DNA and reduces its binding to LEM domain-containing proteins . Down-regulates the transactivation of transcription induced by ERBB2, HRAS, BRAF, and MEK1 . Blocks the phosphorylation of ERK in response to ERBB2 and HRAS . Can also phosphorylate the following substrates that are commonly used to establish in vitro kinase activity: casein, MBP and histone H2B, but it is not sure that this is physiologically relevant . .; FUNCTION: [Isoform 2]: Phosphorylates 'Thr-18' of p53/TP53, as well as histone H3. Reduces p53/TP53 ubiquitination by MDM2, promotes p53/TP53 acetylation by EP300 and thereby increases p53/TP53 stability and activity. . |
Accessions | ENST00000435505.6 [Q86Y07-1] E9PBU1 ENST00000417641.6 [Q86Y07-5] Q86Y07 ENST00000412104.6 [Q86Y07-4] ENST00000440705.6 [Q86Y07-3] Q05CR6 ENST00000428021.1 E7ERS5 ENST00000432057.2 ENST00000648897.1 [Q86Y07-2] ENST00000340157.9 [Q86Y07-1] |